Fibromun (L19-TNF) is a fully-human immunomodulatory product, currently being tested in clinical trials in patients with cancer. It consists of the anti-EDB human antibody L19, fused to human TNF, a strong pro-inflammatory cytokine. Recombinant TNF (Beromun®, Boehringer Ingelheim) has so far been approved only for certain clinical applications.
Fibromun has previously been studied in clinical trials in Melanoma in the Isolated Limb-Perfusion setting and in a systemic clinical trial.
ON-GOING CLINICAL TRIALS
Hemmerle and Neri (2013) Br. J. Cancer 109 (5) 1206-13;
Papadia et al. (2013) J Surg Oncol., 107, 173-179;
Spitaleri et al (2013) J Cancer Res. Clin. Onc., 139, 447-455;
Balza et al. (2010) Int. J. Cancer, 127 (1) 101-10;
Balza et al. (2006) Clin. Cancer Res., 12, 2575-2582;
Borsi et al. (2003) Blood, 102, 4384-4392;
Halin et al (2003) Cancer Res., 63 (12) 3202-10.